gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females

NCT00133497 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

409

Enrollment

NIH

Sponsor class

Conditions

Cytomegalovirus Infections

Interventions

BIOLOGICAL: MF-59
DRUG: Placebo
BIOLOGICAL: CMV gB vaccine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)